KEY HIGHLIGHTS

  • 78 of 80 required events recorded in Phase 3 REGAL trial — topline data imminent.
  • Galinpepimut-S targets AML in complete remission, addressing a high-relapse population with few Options.
  • Phase 2 SLS009 programme continues in frontline AML, deepening the oncology pipeline.
  • Q1 2026 cash balance of $107.1 million funds operations well beyond the REGAL readout.
  • Positive data could establish galinpepimut-S as a first-in-class post-remission immunotherapy.

 

SELLAS Life Sciences Group stands at an inflection point. With 78 of the 80 required events now recorded in its pivotal Phase 3 REGAL trial of galinpepimut-S, the New York-based biotechnology company is days — perhaps weeks — away from a topline data readout that could reshape the treatment landscape for acute myeloid leukaemia.

The REGAL study is evaluating galinpepimut-S, a Wilms Tumour 1 antigen-targeting immunotherapy, in adult patients with AML in complete remission following standard induction chemotherapy. The disease remains one of oncology's most intractable challenges. Relapse rates are high, salvage options are limited, and long-term survival remains elusive for the majority of patients. A therapy capable of prolonging remission would address a glaring gap in the treatment armamentarium.

The company has been methodical in its execution. Event-driven trial designs, by nature, require patience — outcomes cannot be forced. That 78 events have now accumulated speaks to the Maturity of the study and the proximity of the readout. Investors and clinicians alike will be watching closely.

Beyond the REGAL trial, SELLAS is advancing SLS009, a CDK9 inhibitor, through Phase 2 development in frontline AML. The asset broadens the company's exposure to haematological malignancies and provides a secondary catalyst should the galinpepimut-S data prove mixed or require further follow-up.

Financial resilience underpins the strategic optionality. With $107.1 million in cash on hand at the close of the first quarter of 2026, SELLAS enters this critical juncture from a position of strength. The Balance Sheet should comfortably fund operations through the REGAL readout and into the next stage of clinical development, reducing reliance on the Capital Markets at a time of maximum clinical uncertainty.

For investors with an appetite for binary-event risk, SELLAS presents a concentrated but potentially high-reward opportunity. Galinpepimut-S has a differentiated mechanism, a clear unmet medical need, and a company behind it with the resources to see the programme through. The next data release will be defining.

Pre-Market Edition  |  For informational purposes only. Not Investment advice.